✦ LIBER ✦

Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer : Results from a phase 2 trial

✍ Scribed by Jorge A. Garcia; Thomas E. Hutson; Dale Shepard; Paul Elson; Robert Dreicer

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 134 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25457

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dasatinib combined with docetaxel for ca

Dasatinib combined with docetaxel for castration-resistant prostate cancer : Results from a phase 1-2 study

✍ John C. Araujo; Paul Mathew; Andrew J. Armstrong; Edward L. Braud; Edwin Posadas 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 2 views

A phase 2 study of estramustine, docetax

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer : Results from Cancer and Leukemia Group B Study 90006

✍ Joel Picus; Susan Halabi; W. Kevin Kelly; Nicholas J. Vogelzang; Young E. Whang; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 2 views

Ixabepilone, mitoxantrone, and prednison

Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy : A phase 2 study of the department of defense prostate cancer clinical trials consortium

✍ Andrea L. Harzstark; Jonathan E. Rosenberg; Vivian K. Weinberg; Jeremy Sharib; C 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB 👁 1 views

Results from a pilot Phase I trial of ge

Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer

✍ George Wilding; Patrick Soulie; Donald Trump; Ashis Das-Gupta; Eric Small 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

Trastuzumab plus docetaxel in HER-2/neu-

Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma : Final results from the California Cancer Consortium screening and Phase II trial

✍ Primo N. Lara Jr.; Karen Giselle Chee; Jeff Longmate; Christopher Ruel; Frederic 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

## Abstract ## BACKGROUND Overexpression of the HER‐2/__neu__ oncoprotein has been reported to occur in ≤ 60% of patients with prostate carcinoma and to correlate with shortened survival. Trastuzumab is a humanized monoclonal antibody to the HER‐2 receptor and has activity against HER‐2–positive b

A phase 2 study of carboplatin plus doce

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel

✍ Robert W. Ross; Tomasz M. Beer; Susanna Jacobus; Glenn J. Bubley; Mary-Ellen Tap 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 2 views

## Abstract ## BACKGROUND. Prostate cancer is the second leading cause of cancer mortality among men in the U.S. To the authors' knowledge, there is no proven, effective, second‐line therapy for docetaxel‐refractory disease. Recent data suggest that platinum salts may be effective when combined wi